Latest Insider Transactions at Exelixis, Inc. (EXEL)
This section provides a real-time view of insider transactions for Exelixis, Inc. (EXEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXELIXIS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXELIXIS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+10.37%
|
$285,000
$6.21 P/Share
|
|
Dec 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,646
-1.26%
|
$78,982
$17.0 P/Share
|
|
Dec 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
18,741
+4.85%
|
-
|
|
Dec 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
1,556
-0.63%
|
$26,452
$17.0 P/Share
|
|
Dec 15
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
8,995
+3.52%
|
-
|
|
Dec 15
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,236
-5.63%
|
$208,012
$17.0 P/Share
|
|
Dec 15
2021
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,478
+17.62%
|
-
|
|
Nov 29
2021
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
196,524
+13.73%
|
-
|
|
Nov 29
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
196,524
-53.51%
|
-
|
|
Nov 24
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
17,236
-6.76%
|
$293,012
$17.25 P/Share
|
|
Nov 19
2021
|
Carl B Feldbaum Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.12%
|
$340,000
$17.62 P/Share
|
|
Nov 19
2021
|
Carl B Feldbaum Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.22%
|
$60,000
$3.13 P/Share
|
|
Nov 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
62,163
-5.14%
|
$1,118,934
$18.1 P/Share
|
|
Nov 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
47,500
-10.35%
|
$855,000
$18.09 P/Share
|
|
Nov 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+9.38%
|
$285,000
$6.21 P/Share
|
|
Nov 15
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
193,780
-11.84%
|
$3,488,040
$18.1 P/Share
|
|
Nov 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
54,611
-2.91%
|
$982,998
$18.1 P/Share
|
|
Nov 15
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
57,713
-4.73%
|
$1,038,834
$18.1 P/Share
|
|
Nov 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
49,490
-5.5%
|
$890,820
$18.1 P/Share
|
|
Nov 01
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,117
-0.8%
|
$112,574
$22.03 P/Share
|
|
Oct 22
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,747
-4.22%
|
$519,687
$21.33 P/Share
|
|
Oct 22
2021
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,002
+13.83%
|
-
|
|
Oct 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
12,883
-1.98%
|
$283,426
$22.02 P/Share
|
|
Oct 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
47,500
-10.35%
|
$997,500
$21.92 P/Share
|
|
Oct 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+9.38%
|
$285,000
$6.21 P/Share
|
|
Sep 30
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,177
-1.72%
|
$143,540
$20.63 P/Share
|
|
Sep 30
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+6.47%
|
-
|
|
Sep 30
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
5,416
-1.75%
|
$108,320
$20.63 P/Share
|
|
Sep 30
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+8.54%
|
-
|
|
Sep 30
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,593
-1.15%
|
$151,860
$20.63 P/Share
|
|
Sep 30
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+4.21%
|
-
|
|
Sep 30
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,573
-2.02%
|
$171,460
$20.63 P/Share
|
|
Sep 30
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
32,567
+7.13%
|
-
|
|
Sep 21
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
55,057
-12.33%
|
$1,101,140
$20.33 P/Share
|
|
Sep 21
2021
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+16.77%
|
$270,000
$3.66 P/Share
|
|
Sep 16
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
25,000
-8.17%
|
$500,000
$20.36 P/Share
|
|
Sep 16
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.55%
|
$25,000
$1.7 P/Share
|
|
Sep 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
47,500
-10.87%
|
$950,000
$20.46 P/Share
|
|
Sep 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+9.8%
|
$285,000
$6.21 P/Share
|
|
Aug 16
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
55,000
-12.37%
|
$990,000
$18.44 P/Share
|
|
Aug 16
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+11.01%
|
$55,000
$1.9 P/Share
|
|
Jul 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.49%
|
$160,000
$4.2 P/Share
|
|
Jul 21
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+5.12%
|
$140,000
$4.2 P/Share
|
|
Jul 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,020,000
$17.47 P/Share
|
|
Jul 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.9 P/Share
|
|
Jul 06
2021
|
Charles Cohen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+14.29%
|
$320,000
$4.72 P/Share
|
|
Jun 17
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,320,000
$22.18 P/Share
|
|
Jun 17
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.9 P/Share
|
|
May 27
2021
|
Julie Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+33.42%
|
-
|
|
May 27
2021
|
George Poste Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+8.64%
|
-
|